Cover Image
市場調查報告書

Moxifloxacin的中國市場分析

Investigation Report on China Moxifloxacin Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 333484
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Moxifloxacin的中國市場分析 Investigation Report on China Moxifloxacin Market, 2010-2019
出版日期: 2015年06月18日 內容資訊: 英文 20 Pages
簡介

Moxifloxacin為第四代奎諾酮類抗菌藥被開發了。1999年自FDA (美國食品藥物管理局) 獲得認證,以「Avelox」的產品名稱上市。中國國內2002年上市。2005年達6000萬人民幣的市場規模,以30.8%年複合成長率(CAGR) 成長,2014年達6億4900萬人民幣。Moxifloxacin為代表性抗菌藥,今後預期市場也將持續成長。

本報告提供中國的Moxifloxacin的市場相關分析、整體市場規模和國內價格趨勢、各企業、各投藥形態的市場佔有率、主要製造商簡介、今後的市場趨勢預測等調查評估。

第1章 Moxifloxacin的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Moxifloxacin市場概況

  • 中國國內的Moxifloxacin專利的申請、認證情形
  • 主要製造商
  • 市場規模

第3章 Moxifloxacin銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的Moxifloxacin市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (銷售額為基礎)
  • 市場佔有率 (銷售量為基礎)

第5章 中國的Moxifloxacin市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (銷售額為基礎)
  • 各劑型的市場佔有率 (銷售量為基礎)

第6章 Moxifloxacin的醫院用標準價格

  • Nanjing Youke Pharmaceutical Co., Ltd
  • The Bayer Group (德國) (商標名:Avelox)

第7章 中國國內的Moxifloxacin的主要製造商

  • Nanjing Youke Pharmaceutical Co., Ltd
  • The Bayer Group (德國)

第8章 中國的Moxifloxacin市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1506226

As the fourth generation of quinolones drugs, moxifloxacin (moxifloxacin hodrochloride) was first introduced to the market by The Bayer Group in Sep. 1999. It is utilized in the treatment of adult patients (aged 18 and above) diagnosed with upper and lower respiratory tract infections, e.g. acute sinusitis, acute exacerbation of chronic bronchitis (AECB), community-acquired pneumonia, and skin and soft issue infection.

Moxifloxacin was put in the market in Sep. 1999. Having received the approval of American Food and Drug Administration (FDA) on Dec10, 1999, Moxifloxacin entered the US under the trade name of "Avelox".

In the second half year of 2002, Moxifloxacin was marketed by The Bayer Group and Beijing Bayer Healthcare Co., Ltd in China. Key markets were major hospitals in large and medium-sized cities in China. Moxifloxacin grew at a rapid pace after entering the Chinese market, with its annual sales value rising from less than CNY 60 million in 2005 to CNY 649 million in 2014 andits CAGR from 2005 to 2014 reaching 30.8%. Moxifloxacin is of great demand in China. Currently, moxifloxacin for sale in China are mainly produced by Nanjing Youke Pharmaceutical CO., Ltd and The Bayer Group whichowns the larger market share of over 95% for sales value in 2014.

As an outstanding antibacterial drug, moxifloxacin is granted with a bright future of application. It is estimated that the moxifloxacin market in China will keep growing in the following few years.

Readers can have access to at least the following information through this report:

  • Market size of Moxifloxacin in China
  • Competitive landscape of Moxifloxacin in the Chinese market
  • prices of Moxifloxacin produced by different enterprises in China
  • market outlook of Moxifloxacin in the Chinese market

The author suggests the following groups of people purchase this report:

  • manufacturers of antibiotic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

Table of Contents

1. Related Concepts of Moxifloxacin

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Moxifloxacin in China

  • 2.1. Patent and Approval Status of Moxifloxacin in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Moxifloxacin in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Moxifloxacin in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Moxifloxacin in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Moxifloxacin in Chinese Hospitals in 2014

  • 6.1. Nanjing Youke Pharmaceutical Co., Ltd
  • 6.2. The Bayer Group (Germany) (Trade Name: Avelox)

7. Major Manufacturers of Moxifloxacin in Chinese Market, 2010-2014

  • 7.1. Nanjing Youke Pharmaceutical Co., Ltd
  • 7.2. The Bayer Group (Germany)

8. Market Outlook of Moxifloxacin in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Moxifloxacin in China
  • Chart Approval Information of Moxifloxacin in China
  • Chart Sales Status of Moxifloxacin in Chinese Market, 2010-2014
  • Chart Sales Value of Moxifloxacin in China, 2010-2014
  • Chart Sales Value of Moxifloxacin in Some Regions of China, 2010-2014
  • Chart Sales Volume of Moxifloxacin in China, 2010-2014
  • Chart Sales Volume of Moxifloxacin in Some Regions of China, 2010-2014
  • Chart Market Share of TOP 2 Manufactures of Moxifloxacin for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Moxifloxacin Produced by Nanjing Youke Pharmaceutical Co., Ltd, 2010-2014
  • Chart Sales Value and Market Share of Moxifloxacin Produced by The Bayer Group (Germany) in China, 2010-2014
  • Chart Sales Value and Market Share of Moxifloxacin Injection in China, 2010-2014
  • Chart Sales Value and Market Share of Moxifloxacin Tablets in China, 2010-2014
  • Chart Price of Moxifloxacin Produced by Nanjing Youke Pharmaceutical Co., Ltd in Some Cities of China in 2014
  • Chart Price of Moxifloxacin Produced by The Bayer Group (Germany) in Some Cities of China in 2014
Back to Top